Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAT2A | P31153 | 8/20 | 0.43 |
| ▸ | KMO | O15229 | 1/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 4/20 | 0.38 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.37 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15793095 | 0.85 | MAPK8 (0.44) | KDM4CMAPK8MAPK9MAPK10 | |
| SCHEMBL10222165 | 0.79 | ADORA2A (0.59) | MAT2AKMOKDM4CMAPK8MAPK9 | |
| SCHEMBL14737731 | 0.79 | ADORA2A (0.44) | KDM4CADORA2AADORA2BTP53SMN1; SMN2 | |
| SCHEMBL30112337 | 0.78 | PDGFRA (0.41) | MAPK8ADORA2AADORA2BNTRK1ESR1 | |
| SCHEMBL17674125 | 0.78 | PDGFRA (0.41) | MAPK8ADORA2AADORA2BNTRK1ESR1 | |
| SCHEMBL25175266 | 0.78 | DDB1 (0.50) | ADORA2AADORA2BESR1 | |
| SCHEMBL17610229 | 0.78 | ATM (0.44) | MAT2AKDM4CADORA2AADORA2BESR1 | |
| SCHEMBL25079222 | 0.78 | ESR1 (0.58) | ADORA2AADORA2BESR1 | |
| SCHEMBL10320957 | 0.78 | NR4A2 (0.42) | MAT2AKMOKDM4CADORA2AADORA2B | |
| SCHEMBL14738559 | 0.77 | KMO (0.43) | MAT2AKMOKDM4CMAPK8ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021067827-A1 | MCL1 INHIBITORS AND USES THEREOF | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2021-04-08 | — | — | WO | disclosed |
| EP-3194387-B1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2019-07-31 | — | — | EP | disclosed |
| EP-3194387-B1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2019-07-31 | — | — | EP | disclosed |
| US-10231957-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-03-19 | — | — | US | disclosed |
| US-10231957-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-03-19 | — | — | US | disclosed |
| US-20180271843-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-09-27 | — | — | US | disclosed |
| US-10016401-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-10016401-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-10016401-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20170326116-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2017-11-16 | — | — | US | disclosed |
| WO-2016044138-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2016-03-24 | — | — | WO | disclosed |
| WO-2016044138-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2016-03-24 | — | — | WO | disclosed |
| EP-2763990-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-08-13 | — | — | EP | disclosed |
| US-8658646-B2 | Pyrrolopyrazine kinase inhibitors | HOFFMANN-LAROCHE INC. (US) | 2014-02-25 | — | — | US | disclosed |
| US-8658646-B2 | Pyrrolopyrazine kinase inhibitors | HOFFMANN-LAROCHE INC. (US) | 2014-02-25 | — | — | US | disclosed |
| US-8658646-B2 | Pyrrolopyrazine kinase inhibitors | HOFFMANN-LAROCHE INC. (US) | 2014-02-25 | — | — | US | disclosed |
| WO-2013030138-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-07 | — | — | WO | disclosed |
| US-20130059834-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN-LA ROCHE INC. | 2013-03-07 | — | — | US | disclosed |
| US-20130059834-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN-LA ROCHE INC. | 2013-03-07 | — | — | US | disclosed |
| US-20130059834-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN-LA ROCHE INC. | 2013-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10016401-B2 | Histone demethylase inhibitors | KDM1B, KDM1A, KDM5A | MAT2A 240/4885KMO 585/4885KDM4C 12/4885 |
| US-20180271843-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM5A | MAT2A 240/4885KMO 585/4885KDM4C 12/4885 |
| US-10231957-B2 | Histone demethylase inhibitors | KDM1B, KDM1A, KDM5A | MAT2A 240/4885KMO 585/4885KDM4C 12/4885 |
| US-20130059834-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | SYK, ZAP70, JAK1 | MAT2A 2959/4885KMO 720/4885KDM4C 1619/4885 |
| US-20170326116-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM5A | MAT2A 240/4885KMO 585/4885KDM4C 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.